Wave Life Sciences Ltd. (WVE) Gains Momentum With Multiple RNA Wins
Wave Life Sciences Ltd. (NASDAQ:WVE) is a Singapore-based clinical-stage biotechnology company developing RNA-based therapies using its proprietary PRISM platform.
Wave Life Sciences Ltd. (WVE)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 18,202,009 | $118,313,059 | 1.99% | |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 15,016,500 | $97,607,250 | +20% | 0.16% |
| 3. | Maverick Capital Lee Ainslie | 8,261,683 | $53,700,940 | 0.81% | |
| 4. | Driehaus Capital Richard Driehaus | 6,531,519 | $42,454,874 | +3% | 0.34% |
| 5. | M28 Capital Marc Elia | 5,664,548 | $36,819,562 | 62.8% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.00 | 2,791,930 | $22,335,440.00 | 16,775,691 | 2024-09-27 | Filing | |
| $5.00 | 3,300,000 | $16,500,000.00 | 13,983,761 | 2023-12-07 | Filing | |
| $5.00 | 1,000,000 | $5,000,000.00 | 18,202,009 | 2023-12-11 | Filing | |
| $5.00 | 1,000,000 | $5,000,000.00 | 19,202,009 | 2023-12-11 | Filing | |
| $2.15 | 9,480,052 | $20,382,111.80 | 17,202,009 | 2022-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.00 | 10,000 | $100,000.00 | 285,217 | 2025-08-22 | Filing | |
| $10.10 | 217,351 | $2,194,810.40 | 121,000 | 2025-08-22 | Filing | |
| $9.25 | 21,000 | $194,250.00 | 40,388 | 2025-08-15 | Filing | |
| $8.81 | 9,670 | $85,192.70 | 29,645 | 2025-08-13 | Filing | |
| $8.75 | 4,872 | $42,630.00 | 5,716,303 | 2025-08-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,996,900 | $21,937,308 | 0.7% | |
| 2. | 1,766,062 | $12,927,574 | 0.67% | |
| 3. | 368,705 | $2,698,920 | 0% | |
| 4. | 350,548 | $2,566,011 | 0.49% | |
| 5. | 258,011 | $1,888,641 | 0% |
News See All
10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...
Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2025 Earnings Call Transcript
Operator: Hello, and welcome to Wave Life Sciences Second Quarter 2025 Earnings Call. [Operator Instructions] Also, as a reminder, this conference is being recorded today.
Wave Life Sciences Unveils Promising Preclinical Data for Obesity Treatment WVE-007 at ADA Scientific Sessions
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the best low priced pharma stocks to buy now.
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
13 Best Healthcare Stocks to Buy Under $10
On June 27, Tiffany McGhee, CEO of Pivotal Advisors, appeared on CNBC to talk about the best course of action for investors amid current market dynamics.
H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release
Wave Life Sciences Ltd. (NASDAQ:WVE) ranks among the best CRISPR stocks to buy. On June 23, H.C. Wainwright maintained its $22 price target and Buy rating on Wave Life Sciences Ltd. (NASDAQ:WVE).
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
10 Best Low Priced Biotech Stocks to Buy Now
On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2024 Earnings Call Transcript
Operator: Good morning and welcome to the Wave Life Sciences Fourth Quarter and Full Year 2024 Earnings Conference Call.
Hedge Fund Resource Center Billionaire Hedge Funds
